Capecitabine Monitoring Requirements
Essential Monitoring Parameters
- Patients receiving capecitabine require close monitoring during the first treatment cycle for toxicity, with particular attention to hand-foot syndrome, diarrhea, and coagulation parameters in those on anticoagulants 1
- Hand-foot syndrome is the most characteristic and frequent adverse effect, occurring in up to 73% of patients, with 11% experiencing grade 3 events 2, 3
- Patients with partial or complete DPD deficiency (3-5% of population) may experience potentially life-threatening toxicity including severe diarrhea 3
- Thrombocytopenia is especially common when capecitabine is combined with other agents 3
- In breast cancer trials, grade 3/4 neutropenia occurred in 6.3% of patients 4
First Cycle Monitoring Protocol
- Close monitoring during the first cycle is essential, with dose adjustments as needed based on toxicity 1
- North American patients may experience greater toxicity than European patients, warranting particularly careful observation 5, 1, 6
- For grade 1 toxicity, continue treatment with close monitoring 3
Special Population Considerations
- Patients over 65 years have significantly higher risk of severe toxicity (34% grade 3 or higher), including treatment-related deaths 4, 3
- Consider starting dose of 1,000 mg/m² twice daily in elderly patients 4, 5
Imaging Surveillance
- Use CT scan with contrast or MRI to monitor treatment progress 1
- Do not use PET/CT for monitoring therapy progress 1